In patients with non‑ST‑segment elevation myocardial infarction (NSTEMI), when should a 162 mg chewable aspirin loading dose be administered instead of a 325 mg tablet?

When to Give 162 mg vs 325 mg Aspirin in NSTEMI

For NSTEMI patients, give 162-325 mg of non-enteric-coated, chewable aspirin as the initial loading dose as soon as possible after presentation—both doses are equally effective, but 162 mg may be safer with less bleeding risk. 1, 2

Initial Loading Dose (First 24 Hours)

The 2014 AHA/ACC NSTEMI guidelines provide a Class I recommendation for non-enteric-coated, chewable aspirin at 162-325 mg to be given immediately upon presentation 1, 2. The key distinction is:

• Both 162 mg and 325 mg are acceptable loading doses
• The aspirin must be chewable and non-enteric-coated to ensure rapid absorption 1
• Enteric-coated formulations should be avoided initially due to delayed and reduced absorption 1

Evidence Supporting Lower Dose (162 mg)

Research directly comparing these doses in STEMI patients (which applies to NSTEMI management) found that 162 mg aspirin was as effective as 325 mg for mortality outcomes but was associated with significantly less bleeding 3. In the GUSTO I and III trials analysis of 48,422 patients:

• No difference in 24-hour, 7-day, or 30-day mortality between doses
• 325 mg associated with 14% increased risk of moderate/severe bleeding (OR 1.14, p=0.003) 3

Pharmacokinetic data confirms that 162 mg chewable aspirin achieves maximum platelet inhibition within 30 minutes, with peak plasma concentrations sufficient for complete antiplatelet effect 4.

Maintenance Dosing After Initial Treatment

After the loading dose, transition to low-dose aspirin (75-100 mg daily, or 81 mg in the US) for long-term maintenance 5:

• Class I recommendation for 81 mg daily maintenance dose 1, 2
• High-dose aspirin (≥160 mg) for maintenance is associated with increased bleeding without improved outcomes 1
• When using ticagrelor specifically, aspirin maintenance must be 81 mg daily (not higher) 1, 5

Clinical Algorithm

At presentation:

1. Administer 162-325 mg chewable, non-enteric-coated aspirin immediately
2. Patient should chew the tablet for faster absorption 5
3. If oral route unavailable, use rectal or IV administration 5

After PCI (if performed):

• Continue 162-325 mg daily for 1 month (bare-metal stent) or 3-6 months (drug-eluting stent) 6, 7
• Then reduce to 81 mg daily indefinitely 1, 2

For medically managed patients (no PCI):

• Transition to 81 mg daily as soon as clinically stable 1, 2

Common Pitfalls

• Don't use enteric-coated aspirin initially—it delays absorption when rapid platelet inhibition is critical 1
• Don't continue high-dose aspirin long-term—bleeding risk increases without additional benefit 1
• Don't exceed 100 mg daily when using ticagrelor—higher doses reduce ticagrelor's efficacy 1, 5
• Don't skip the loading dose even if patient is already on daily aspirin—the loading dose is still indicated 5

The most recent 2025 ACC/AHA guidelines reinforce that 162-325 mg loading dose followed by 75-100 mg daily maintenance represents the optimal evidence-based approach, with the lower end of both ranges (162 mg loading, 75-81 mg maintenance) offering the best balance of efficacy and safety 5.